Top Manufacturer Adopts Digital Twin
A top-five global life sciences manufacturer has reportedly selected a digital twin platform for implementation in its biomanufacturing operations. The move signals growing industry confidence in using digital twin technology to support process optimization and compliance within GMP environments. This adoption by a major player could accelerate the use of digital twins from pilot phases to core operational systems across the sector.
- The global digital biomanufacturing market is projected to grow from USD 2 billion in the current year to USD 12.3 billion by 2035, expanding at a compound annual growth rate (CAGR) of 17.9%. Technologies focused on digital twins are expected to see an annualized growth of 19%. - In cell and gene therapy, digital twins are being developed to address manufacturing challenges, such as optimizing the conditions for T-cell expansion. For instance, the CGT Catapult and University College London are collaborating on a digital twin to identify and control optimal nutrient levels and timing for process steps in CAR-T manufacturing. - Digital twin platforms often integrate several key technologies, including computational fluid dynamics (CFD) to simulate physical conditions in bioreactors, mechanistic models for cell growth kinetics, and machine learning for predictive analytics and pattern recognition. Key software components include data integration tools like Rockwell Automation's FactoryTalk, simulation software such as Aspen BioProcess Designer, and analytics platforms like Siemens Xcelerator. - Implementation can reduce production downtime by 20–25% and cut quality control costs by up to 45%. Forward-looking pharmaceutical companies have used digital twins to reduce engineering and validation time by 40–70% by simulating control logic and processes before physical execution. - Digital twins enhance regulatory compliance by maintaining accurate, contemporaneous records that align with ALCOA+ principles. This simplifies audit preparation and supports the continuous verification approaches accepted under ICH Q8/Q10 guidelines. - Major players in the life sciences digital twin space include Dassault Systèmes, with its "Virtual Twin of Humans" initiative, and technology providers like Siemens and GE Digital. Sanofi's facility in Framingham, Massachusetts, uses digital twins to simulate process changes *in silico* before applying them to the actual product. - Key challenges to widespread adoption include the high initial investment, the need for specialized expertise in AI and systems biology, and ensuring seamless data integration from diverse sources like sensors and enterprise systems. Many current implementations are still in pilot stages due to fragmented data sources and concerns over model validation. - For contract development and manufacturing organizations (CDMOs), digital twins can model a sponsor's process using the specific geometry of the CDMO's commercial-scale bioreactors. This helps to proactively identify scale-dependent risks such as shear stress or poor oxygen transfer before initiating expensive cGMP batches.
